Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05145569 | Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Jan 1, 2025 | clinicaltrials |
| NCT04260230 | Remote Monitoring of Patients at Risk of Sepsis(REACT) | withdrawn | N/A | 0 | The Christie NHS Foundation TrustOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05861336 | GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer(OVERPASS) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04889066 | Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | withdrawn | Early Phase 1 | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT05640115 | Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent | withdrawn | Early Phase 1 | 0 | University of ChicagoOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT04093557 | Improving Outpatient Colonoscopy Bowel Prep With the Orton Score | withdrawn | N/A | 0 | University of VirginiaOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05094544 | Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC(POIMS) | withdrawn | N/A | 0 | University of Kansas Medical CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT01350180 | Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis | withdrawn | — | 0 | Dr. Tamim NiaziOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02347839 | NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.(NEGOTIATE) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02428764 | Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02588404 | The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient | withdrawn | — | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 10, 2024 | clinicaltrials |
| NCT03164694 | APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC(APPEAL) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06227897 | Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).(AERESA) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer(Breast50) | withdrawn | Early Phase 1 | 0 | University of VirginiaOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT03802747 | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | withdrawn | Phase 1 | 0 | University of Colorado, DenverOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | withdrawn | Phase 2 | 0 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722885 | Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System(SBRT_LOV) | withdrawn | — | 0 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02883361 | Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors(MI for AIs) | withdrawn | Phase 2 / Phase 3 | 0 | University of CalgaryOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03939585 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT | withdrawn | Phase 1 | 0 | Leland MethenyOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT02699229 | Non-linear Multimodal Microendoscopy for Lung Cancer Pathology | withdrawn | — | 0 | University Health Network, TorontoOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Tel Aviv Medical CenterOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT04530019 | Brachytherapy Innovations in Gynecologic Cancer | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Nov 29, 2024 | clinicaltrials |
| NCT03622528 | Quantitative Lung Cancer Screening | withdrawn | — | 0 | Jessica SierenOTHER | 0 | Nov 27, 2024 | clinicaltrials |
| NCT04160182 | Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors | withdrawn | N/A | 0 | University of Toledo Health Science CampusOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04232319 | Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors | withdrawn | N/A | 0 | University of Toledo Health Science CampusOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04272294 | Functional and Molecular Characterization of Treatment Response in Tumors in the Oral Cavity Using Optical Spectroscopy | withdrawn | N/A | 0 | University of ArkansasOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT05427344 | Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients | withdrawn | N/A | 0 | Tel Aviv UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06654258 | Supporting Spiritual Wellbeing in Young Adults With Cancer Using a Digital Health Approach: A Feasibility Study | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona | withdrawn | N/A | 0 | University of ArizonaOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06207786 | Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery | withdrawn | N/A | 0 | Mayo ClinicOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.(ABLE-42) | withdrawn | Phase 4 | 0 | Ferring PharmaceuticalsINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Nov 21, 2024 | clinicaltrials |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06068153 | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC(AMBER) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 4 | Nov 20, 2024 | clinicaltrials |
| NCT04007549 | Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer Treatment.(IBMC) | withdrawn | N/A | 0 | Institut BergoniéOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Kathleen DorritieOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT02588846 | Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM(KOALA) | withdrawn | N/A | 0 | Royal North Shore HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06217536 | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Nov 18, 2024 | clinicaltrials |
| NCT03228043 | Apatinib for Resectable Colorectal Cancer | withdrawn | N/A | 0 | Nanchong Central HospitalOTHER_GOV | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05266950 | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06023368 | Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray | withdrawn | Phase 4 | 0 | Marianne HuttiOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06003179 | Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah(LOKI) | withdrawn | Phase 1 | 0 | University Health Network, TorontoOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06017297 | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma(ESR-22-21719) | withdrawn | Phase 2 | 0 | Georgetown UniversityOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT06377202 | Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies | withdrawn | — | 0 | Verismo TherapeuticsINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03990194 | Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer(LEPTO) | withdrawn | — | 0 | RECORDATI GROUPINDUSTRY | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Oct 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 1, 2025source: clinicaltrials